Riluzole
Evidence-based neurology checklist on riluzole: Pharmacology Riluzole is a benzothiazole derivative It inhibits presynaptic glutamate release It is indicated for both ALS and PMA Benefits Dosing and administration Monitoring Side effects Acronyms
Pharmacology
- Riluzole is a benzothiazole derivative
- It inhibits presynaptic glutamate release
- It is indicated for both ALS and PMA
Benefits
Dosing and administration
Monitoring
Side effects
Acronyms
References
- Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies. Neurology 2009; 73:1228-1226.
- Miller RG, Jackson CE, Kasarskis RJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioural impairment (an evidence-based review). Neurology 2009; 73:1227-1233.
- Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. JNNP 2003; 74(Suppl IV):iv32-iv47.
- Mazumder S, McCann H, D'Silva S, et al. Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis. Brain 2023; 146:e17-e19.
- Thakore NJ, Lapin BR, Mitsumoto H, Pooled Resource Open-Access ALS Clinical Trials Consortium. Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis. Muscle Nerve 2022; 66:702-708.
- And 4 more. Subscribe to see the full list
